Importance Improvement in left ventricular ejection fraction (EF) to> 35% occurs in many
patients with reduced EF at baseline. To our knowledge, whether implantable cardioverter …

BACKGROUND: Although implantable cardioverter defibrillators (ICDs) are increasingly
used in advanced (class III/IV) heart failure, their benefits may be limited by death from pump …

Background—The Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT) demonstrated
that implantable cardioverter-defibrillator (ICD) therapy reduces all-cause mortality in …

Background—Whether patients with heart failure derive a benefit from therapy with
implantable cardioverter-defibrillators (ICDs) has been questioned. The purpose of this …

Background—The clinical effectiveness of implantable cardioverter-defibrillators (ICDs) in
older patients with heart failure has not been established, and older patients have been …

Background Many current predictors of mortality in heart failure (HF) were evaluated before
the use of implantable cardioverter defibrillators (ICDs). We conducted a meta-analysis to …

In a systematic review1 of 12 randomized controlled trials (RCTs) accounting for a total of
8516 patients with left ventricular (LV) systolic dysfunction (regardless of whether the …

Background: Most randomized trials on implantable cardioverter-defibrillator (ICD) use for
primary prevention of sudden cardiac death in heart failure with reduced ejection fraction …

Background Current guidelines for the primary prevention of sudden cardiac death have
used a left ventricular ejection fraction (LVEF)≤ 35% as a critical point to justify implantable …

Current guidelines for use of implantable cardioverter-defibrillators (ICDs) for primary
prevention of sudden death in patients with coronary disease and nonischemic dilated …